ALEXANDRIA, Va., Aug. 18 -- United States Patent no. 12,708,607, issued on Aug. 18, was assigned to ATXA THERAPEUTICS Ltd. (Dublin).
"Thromboxane receptor antagonist formulations" was invented by B. Therese Kinsella (Dublin), Helen Reid (Dublin) and Eamon Mulvaney (Dublin).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides formulations that enhances bioavailability of thromboxane receptor antagonists allowing them to bind to the thromboxane A2 receptors in subjects suffering from disease indications in which the prostanoid thromboxane A2, and incidental thromboxane A2 receptor ligands, are implicated. The formulations comprise a solid dispersion comprising a benzenesulfonyl urea and...